🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are increasing around the world, with data suggesting over 82 million new cases per year. Particularly high rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the context of rising global incidence, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, gained clearance in the same week. This medication, which is employed against UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This milestone marks a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Results and Worldwide Availability

As per data detailed in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This establishes an comparable level with the typical regimen, which combines two antibiotics. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have expressed hope. Access to a single-dose, oral treatment like this is described as a "game-changer" for gonorrhoea control. This is viewed as crucial to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.